Results 71 to 80 of about 28,042 (215)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin

, 2017
International audienceBACKGROUND: Heart failure with reduced ejection fraction (HFrEF) exhibits a "reverse metabolic profile". Whether this profile exists in HF with preserved ejection fraction (HFpEF) is unknown.
Faxén, Ulrika Ljung, Donal, Erwan, Lund, Lars H., Brismar, Kerstin, Hage, Camilla, Linde, Cecilia, Andreasson, Anna, Andreasson, Anna,, Daubert, Jean-Claude, Ljung Faxen, Ulrika   +9 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Features of HFREF Latent Class Model B subtypes.

, 2012
Features of HFREF Latent Class Model B subtypes.
David P. Kao (122820), Brandie D. Wagner (122824), Michael R. Bristow (122833), Brian D. Lowes (122837), Alastair D. Robertson (122829)   +4 more
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1

, 2017
International audienceBACKGROUND: Anabolic drive is impaired in heart failure with reduced ejection fraction (HFrEF) but insufficiently studied in heart failure with preserved ejection fraction (HFpEF).
Faxén, Ulrika Ljung, Donal, Erwan, Lund, Lars H., Brismar, Kerstin, Hage, Camilla, Benson, Lina, Linde, Cecilia, Andreasson, Anna, Daubert, Jean-Claude, Zabarovskaja, Stanislava   +9 more
core   +1 more source

cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events. [PDF]

, 2020
BACKGROUND: Cardiac Bridging Integrator 1 (cBIN1) is a membrane deformation protein that generates calcium microdomains at cardiomyocyte t-tubules, whose transcription is reduced in heart failure, and is released into blood.
Caldaruse, Ana-Maria, Hong, TingTing, Kobashigawa, Jon, Geft, Dael, Zadikany, Ronit, Melmed, Gil, Czer, Lawrence, Kittleson, Michelle, Hamilton, Michele, Nikolova, Andriana, Baum, Rachel, McGovern, Dermot, Xie, Yu, Agvanian, Sosse, Shaw, Robin, Moriguchi, Jaime, Azarbal, Babak, Hitzeman, Tara, Wu, Alan, Hage, Antoine, Patel, Jignesh, Chang, David   +21 more
core   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model

Clinical Epidemiology, 2020
Moa P Lee,1,2 Robert J Glynn,1 Sebastian Schneeweiss,1 Kueiyu Joshua Lin,1,3 Elisabetta Patorno,1 Julie Barberio,1 Raisa Levin,1 Thomas Evers,4 Shirley V Wang,1 Rishi J Desai1 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women ...
Lee MP, Glynn RJ, Schneeweiss S, Lin KJ, Patorno E, Barberio J, Levin R, Evers T, Wang SV, Desai RJ   +9 more
doaj  

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source